 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | LAVA-1266 / LAVA Therap
New P1 trial, Immune cell: A clinical trial to assess the safety, distribution, effects on certain immune cells and anti-leukaemia effects of LAVA-1266 in patients with acute myeloid leukaemia or certain types of myelodysplastic syndrome (EUDRACT) - Oct 4, 2024
P1, N=50, Not yet recruiting, Sponsor: LAVA Therapeutics N.V.